Negotiating Medical Insurance Drug Prices: The Role in Reducing Costs of Orphan Drugs for Rare Diseases

Document Type : Letter to Editor

Authors

1 Department of Clinical Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, China

2 NHC Key Laboratory of Health Technology Assessment, Department of Health Economics, School of Public Health, Fudan University, Shanghai, China

Abstract

Negotiating Medical Insurance Drug Prices: The Role in Reducing Costs of Orphan Drugs for Rare Diseases

Keywords

Full Text

Dear Editor,

 

There are 20 million patients with rare diseases in China, and over 200 000 new patients are diagnosed each year. In 2018, the Chinese government identified the first batch of rare diseases, which included 121 conditions. Drugs developed for rare diseases (orphan drugs) are often prohibitively expensive for most families, making their availability and affordability a recurring topic in literature.1 The global challenge of ensuring equitable access to treatment for rare diseases has gained much attention. ...(Read more...)

References

  1. Adachi T, El-Hattab AW, Jain R, et al. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. Int J Environ Res Public Health. 2023;20(6):4732. doi:3390/ijerph20064732
  2. Wong WB, Seetasith A, Hung A, Zullig LL. Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs. PLoS One. 2023;18(1):e0280570. doi:1371/journal.pone.0280570
  3. Guo X. Why does price control policies do not apply in the US pharmaceutical market, as opposed to many EU markets? Front Manage Sci. 2023;2(1):81-90. doi:56397/fms.2023.02.07
  4. Towse A, Kettler H. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. Bull World Health Organ. 2005;83(4):301-307.
  5. World Health Organization (WHO). Designing Health Financing Systems to Reduce Catastrophic Health Expenditure. WHO; 2005.
  6. Dickson S, Hernandez I. Drugs likely subject to Medicare negotiation, 2026-2028. J Manag Care Spec Pharm. 2023;29(3):229-235. doi:18553/jmcp.2023.29.3.229
  7. Fu R, Chen Q, Lin Y, Lin Z, Zheng Z, Hu Z. Short-term and long-term effects of Sanming healthcare system reform on drug-related expenditures for rural patients with cancer in public hospitals: an interrupted time series analysis using segmented regression model in China. BMJ Open. 2023;13(1):e065586. doi:1136/bmjopen-2022-065586

Files

History

  • Receive Date: 13 July 2023
  • Revise Date: 13 August 2023
  • Accept Date: 16 October 2023
  • First Publish Date: 17 October 2023

Share

How to cite

Statistics